Skip to main content

An ovarian cancer clinical trial - I240C

A study of a new drug combination in patients with advanced ovarian cancer
Disease Site
Investigational New Drug Program
Trial Code
IND.240C ǀ NCT04918186
Trial Status
Open to patient enrollment

What is the purpose of this study?

The purpose of this study is to test the good and bad effects of a combination of new drugs on you and your advanced ovarian cancer for which platinum based chemotherapy is no longer an option.

Why is this study important?

The new drugs have shrunk or stabilized your type of cancer in a limited number of people and in animal testing, but it is not clear if they can offer better results than standard treatment. This study may help the study doctors learn things that may help other people in the future.

Who can participate in this study?

This trial is for:

  • people diagnosed with high grade serous or clear cell cancer originating from the ovaries, fallopian tubes or peritoneum
  • people for whom treatment with platinum-based chemotherapy is no longer an option

This trial is not for:

  • who have other uncontrolled or serious illnesses or medical conditions that could put safety at risk during the clinical trial
  • with cancer that has spread to the central nervous system
  • who would need to receive treatment with other cancer therapies
  • who have autoimmune or inflammatory diseases

You will find complete details of who this trial is for by visiting https://www.clinicaltrials.gov/study/NCT04918186

What are the risks?
  • If you choose to take part in this study, there is a risk that the new drugs may not be as good at shrinking or stabilizing your cancer as the usual approach for your cancer. There is also a risk that you could have side effects from the new drugs. Some of the most common side effects that the study doctors know about are: changes to hormone glands and liver function as seen on blood tests and a decrease in the number of platelets, white blood cells, or red blood cells. These effects could be worse or different than you would get with the usual approach for your cancer.
  • You will find details of all side effects in the consent document.
What can I expect?
  • If you choose to take part in this study, you will receive the two new drugs.

How can I find out more or join the study?

Talk to your cancer doctor if you are considering joining this study. You can share summaries like this with them and ask if they think joining the trial may be a good option for you.

Before you join this study, you will be asked to review an Informed Consent document which will tell you more about why the research is being done and your role as a participant. You will have an opportunity to discuss anything that is not clear and ask any questions you have.

Joining this study is entirely up to you and you can decide to leave at any time without giving a reason. Your decision to join or leave the trial will not affect your standard medical care.

The IND.240C study is currently enrolling patients at cancer centres. For a full list of participating cancer centres please visit https://www.clinicaltrials.gov/study/NCT04918186

Use this trial information for your conversation with your health care team

Participating centres

Information coming soon.